Search
DP-VPA
go.drugbank.com/drugs/DB05821InvestigationalDP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure
Trodusquemine
go.drugbank.com/drugs/DB06333InvestigationalIt has demonstrated the ability to stimulate regeneration of heart and multiple other tissues in animal models [A176600].
Calcimycin
go.drugbank.com/drugs/DB19408InvestigationalCalcimycin is an ionophore and polyether antibiotic derived from Streptomyces chartreusensis. … It binds to and transports calcium and other divalent cations across membranes, disrupts oxidative phosphorylation, and inhibits ATPase in rat liver mitochondria.
Categories: Compounds used in a research, industrial, or household settingSulfadiazine
go.drugbank.com/drugs/DB00359ApprovedInvestigationalVet approvedOne of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.
Synonyms: N(1)-2-Pyrimidylsulfanilamide, N(1)-2-PyrimidinylsulfanilamidePSN9301
go.drugbank.com/drugs/DB05001ExperimentalPSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.
Theobromine
go.drugbank.com/drugs/DB01412Investigational(From Martindale, The Extra Pharmacopoeia, 30th ed, pp1318-9) … It has practically no stimulant effect on the central nervous system. It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension.
Volixibat
go.drugbank.com/drugs/DB13914Investigationalthe liver have been implicated in its pathogenesis[A32119]. … Inhibiting this enzyme results in a decrease of bile acids returning to the liver, which is helpful for the treatment of NASH as abnormal cholesterol metabolism and accumulation of free cholesterol in
Efalizumab
go.drugbank.com/drugs/DB00095ApprovedWithdrawnThe FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797] … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.
Propyl Gallate
go.drugbank.com/drugs/DB12450InvestigationalPropyl Gallate is under investigation in clinical trial NCT01450098 (A Study of LY2484595 in Healthy Subjects).
Categories: Compounds used in a research, industrial, or household setting